Where can I find IMED.TA's financial statements?

Imed Infinity Medical-Limited Partnership (IMED.TA)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.

How much history is available for IMED.TA?

Imed Infinity Medical-Limited Partnership (IMED.TA) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.

How often does IMED.TA update its statements?

Imed Infinity Medical-Limited Partnership files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

IMED.TA

Imed Infinity Medical-Limited Partnership

TLV·Medical, Healthcare Information Services · Healthcare

ILA 88.60ILA 0.00+0.00%

Market capILA 604.70M·Aug 18 1:16 PM UTC

USD · values shown as reported

Line item	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Trend
Revenue	$75.00K	$200.00K+166.7%	−$942.00K−571.0%	$41.00K+104.4%	$0.00−100.0%
Cost of revenue	—	—	—	—	$88.76K	—
Gross profit	$75.00K	$200.00K+166.7%	−$942.00K−571.0%	$41.00K+104.4%	−$88.76K−316.5%
Research & development	$10.20M	$10.60M+3.9%	$16.00M+50.9%	$17.80M+11.3%	—
General & administrative	$902.00K+1,152.8%	$785.00K−13.0%	$784.00K−0.1%	$616.00K−21.4%	—
Selling & marketing	$30.00K−50.0%	$30.00K+0.0%	$7.00K−76.7%	$6.00K−14.3%	—
SG&A (combined)	$968.00K+611.8%	$815.00K−15.8%	$791.00K−2.9%	$622.00K−21.4%	—
Other operating expenses	−$10.20M	−$10.60M−3.9%	−$16.00M−50.9%	−$17.80M−11.3%	$372.37K+102.1%
Total operating expenses	$968.00K+611.8%	$815.00K−15.8%	$791.00K−2.9%	$622.00K−21.4%	$372.37K−40.1%
Operating income	−$893.00K−556.6%	−$615.00K+31.1%	−$1.73M−181.8%	−$581.00K+66.5%	−$461.13K+20.6%
Interest income	$394.12K	—	—	$6.00K	—
Interest expense	—	$391.00K	$37.00K−90.5%	—	—
Other income / (expense), net	$127.00K	−$391.00K−407.9%	−$37.00K+90.5%	$6.00K+116.2%	$253.30K+4,121.6%
Income before tax	−$766.00K−463.2%	−$1.01M−31.3%	−$1.77M−75.9%	−$575.00K+67.5%	−$207.83K+63.9%
Net income	−$766.00K−463.2%	−$1.01M−31.3%	−$1.77M−75.9%	−$575.00K+67.5%	−$147.22K+74.4%

EPS (basic)	−$0.19−588.4%	−$0.25−31.6%	−$0.44−76.0%	−$0.14+68.2%	−$0.03+77.6%
EPS (diluted)	−$0.19−588.4%	−$0.25−31.6%	−$0.44−76.0%	−$0.14+68.2%	−$0.03+77.6%
Weighted avg shares (basic)	4,031,577	4,024,000	4,022,726	4,107,141	4,533,333
Weighted avg shares (diluted)	4,031,577	4,024,000	4,022,726	4,107,141	4,533,333

Depreciation & amortization	$893.00K+556.6%	$615.00K−31.1%	$1.73M+181.8%	$581.00K−66.5%	—
EBITDA	$0.00	$0.00	$0.00	$0.00	−$207.83K

Frequently Asked Questions About IMED.TA

Where can I find IMED.TA's financial statements?: Imed Infinity Medical-Limited Partnership (IMED.TA)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.
How much history is available for IMED.TA?: Imed Infinity Medical-Limited Partnership (IMED.TA) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.
How often does IMED.TA update its statements?: Imed Infinity Medical-Limited Partnership files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

Line item

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Trend

Revenue

$75.00K

$200.00K+166.7%

−$942.00K−571.0%

$41.00K+104.4%

$0.00−100.0%

Cost of revenue

—

$88.76K

—

Gross profit

$75.00K

$200.00K+166.7%

−$942.00K−571.0%

$41.00K+104.4%

−$88.76K−316.5%

Research & development

$10.20M

$10.60M+3.9%

$16.00M+50.9%

$17.80M+11.3%

—

General & administrative

$902.00K+1,152.8%

$785.00K−13.0%

$784.00K−0.1%

$616.00K−21.4%

—

Selling & marketing

$30.00K−50.0%

$30.00K+0.0%

$7.00K−76.7%

$6.00K−14.3%

—

SG&A (combined)

$968.00K+611.8%

$815.00K−15.8%

$791.00K−2.9%

$622.00K−21.4%

—

Other operating expenses

−$10.20M

−$10.60M−3.9%

−$16.00M−50.9%

−$17.80M−11.3%

$372.37K+102.1%

Total operating expenses

$968.00K+611.8%

$815.00K−15.8%

$791.00K−2.9%

$622.00K−21.4%

$372.37K−40.1%

Operating income

−$893.00K−556.6%

−$615.00K+31.1%

−$1.73M−181.8%

−$581.00K+66.5%

−$461.13K+20.6%

Interest income

$394.12K

—

$6.00K

—

Interest expense

—

$391.00K

$37.00K−90.5%

—

Other income / (expense), net

$127.00K

−$391.00K−407.9%

−$37.00K+90.5%

$6.00K+116.2%

$253.30K+4,121.6%

Income before tax

−$766.00K−463.2%

−$1.01M−31.3%

−$1.77M−75.9%

−$575.00K+67.5%

−$207.83K+63.9%

Net income

−$766.00K−463.2%

−$1.01M−31.3%

−$1.77M−75.9%

−$575.00K+67.5%

−$147.22K+74.4%

EPS (basic)

−$0.19−588.4%

−$0.25−31.6%

−$0.44−76.0%

−$0.14+68.2%

−$0.03+77.6%

EPS (diluted)

−$0.19−588.4%

−$0.25−31.6%

−$0.44−76.0%

−$0.14+68.2%

−$0.03+77.6%

Weighted avg shares (basic)

4,031,577

4,024,000

4,022,726

4,107,141

4,533,333

Weighted avg shares (diluted)

4,031,577

4,024,000

4,022,726

4,107,141

4,533,333

Depreciation & amortization

$893.00K+556.6%

$615.00K−31.1%

$1.73M+181.8%

$581.00K−66.5%

—

EBITDA

$0.00

−$207.83K